Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Arthritis Care & Research|September 9, 2010
Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patientsCharles Sèbiyo Batcho, Patrick Durez, Jean-Louis Thonnard
Clinical and Experimental Rheumatology|March 31, 2018
Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature reviewBernard Combe, Sadiq Lula, Caroline Boone, et al.
BMJ Case Reports|November 24, 2017
Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreasMarc Plier, Patrick Durez, Mina Komuta, et al.
Nephrologie & Therapeutique|November 8, 2018
[Life-threatening hypercalcemia and acute kidney injury induced by etanercept]Yawovi Mawufemo Tsevi, Selda Aydin, Patrick Durez, et al.
BMJ Case Reports|January 30, 2021
Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitisCharlotte Anne Baert, Selda Aydin, Philippe Leroy, et al.
Clinical Rheumatology|June 21, 2007
Listeria infections associated with infliximab: case reportsThomas Kesteman, Jean-Cyr Yombi, Jacques Gigi, et al.
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Joint Bone Spine|April 1, 2019
Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment targetJulie Legrand, Thomas Kirchgesner, Tatiana Sokolova, et al.
European Journal of Radiology|November 22, 2020
Comparison between 3-point Dixon- and CHESS-based OMERACT-recommended MRI protocols in hands of patients with suspicion of early rheumatoid arthritisThomas Kirchgesner, Maria Stoenoiu, Nicolas Michoux, et al.
The Lancet. Rheumatology|October 17, 2025
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritisClément Triaille, Patrick Durez, Francesco Natalucci, et al.
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Arthritis Care & Research|September 9, 2010
Responsiveness of the ABILHAND questionnaire in measuring changes in rheumatoid arthritis patientsCharles Sèbiyo Batcho, Patrick Durez, Jean-Louis Thonnard
Clinical and Experimental Rheumatology|March 31, 2018
Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature reviewBernard Combe, Sadiq Lula, Caroline Boone, et al.
BMJ Case Reports|November 24, 2017
Severe panniculitis and polyarthritis caused by acinar cell carcinoma arising from an ectopic pancreasMarc Plier, Patrick Durez, Mina Komuta, et al.
Nephrologie & Therapeutique|November 8, 2018
[Life-threatening hypercalcemia and acute kidney injury induced by etanercept]Yawovi Mawufemo Tsevi, Selda Aydin, Patrick Durez, et al.
BMJ Case Reports|January 30, 2021
Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitisCharlotte Anne Baert, Selda Aydin, Philippe Leroy, et al.
Clinical Rheumatology|June 21, 2007
Listeria infections associated with infliximab: case reportsThomas Kesteman, Jean-Cyr Yombi, Jacques Gigi, et al.
Arthritis Research & Therapy|May 13, 2010
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activityBert Vander Cruyssen, Patrick Durez, Rene Westhovens, et al.
Joint Bone Spine|April 1, 2019
Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment targetJulie Legrand, Thomas Kirchgesner, Tatiana Sokolova, et al.
European Journal of Radiology|November 22, 2020
Comparison between 3-point Dixon- and CHESS-based OMERACT-recommended MRI protocols in hands of patients with suspicion of early rheumatoid arthritisThomas Kirchgesner, Maria Stoenoiu, Nicolas Michoux, et al.
The Lancet. Rheumatology|October 17, 2025
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritisClément Triaille, Patrick Durez, Francesco Natalucci, et al.
Pageof 12